CoChat

Functional characterization of 22 novel CYP2D6 variants for the metabolism of Tamoxifen

Hu, Xiao-Xia, Zhou, Quan, Lan, Tian, Huang, Xiang-Xin, Liang, Bing-qing, Dai, Da-Peng, Cai, Jian-Ping, Hu, Guo-Xin · 2016 · Journal of Pharmacy and Pharmacology
Cited by 6

The DOI matches its Crossref record.

Abstract

Objectives: This study aimed to assess the catalytic characteristics of 24 CYP2D6 allelic isoforms found in Chinese Han population on the metabolism of tamoxifen in vitro. Methods: Recombinant CYP2D6 microsomes of distinguished genotypes were used to characterize the corresponding enzyme activity towards tamoxifen. About 5–2500 μm tamoxifen was incubated for 30 min at 37 °C. Using high-performance liquid chromatography to detect the products, the kinetic parameters Km, Vmax and intrinsic clearance (Vmax/Km) of N-desmethyltamoxifen were determined. Key findings: Of the 24 tested allelic variants, the differences of intrinsic clearance value were shown as follows: CYP2D6.89 was much higher than wild-type CYP2D6.1, 2 allelic isoforms (CYP2D6.88 and D336N) exhibited similar intrinsic clearance values as the wild-type enzyme, two variants displayed weak or no activity, while the rest 19 variants showed significantly reduced intrinsic clearance values ranging from 7.46 to 81.11%. Conclusion: The comprehensive assessment of CYP2D6 variants provides significant insights into allele-specific activity towards tamoxifen in vitro, suggesting that most of the carriers of these alleles might be paid more attention when using CYP2D6-mediated drugs clinically.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jphp.12556

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 25

  1. Guengerich, 2008, Cytochrome P450 and chemical toxicology, Chem Res Toxicol, 21, 70, 10.1021/tx700079z · DOI · Paper page
  2. Jin, 2013, Polymorphisms and phenotypic analysis of cytochrome P450 2D6 in the Tibetan population, Gene, 527, 360, 10.1016/j.gene.2013.03.110 · doi:10.1016/j.gene.2013.03.110
  3. Zanger, 2004, Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry, Naunyn Schmiedebergs Arch Pharmacol, 369, 23, 10.1007/s00210-003-0832-2 · DOI · Paper page
  4. Bonifacio, 2006, Binding of bufuralol, dextromethorphan, and 3,4-methylenedioxymethylamphetamine to wild-type and F120A mutant cytochrome P450 2D6 studied by resonance Raman spectroscopy, Biochem Biophys Res Commun, 343, 772, 10.1016/j.bbrc.2006.03.027 · doi:10.1016/j.bbrc.2006.03.027
  5. Zafra-Ceres, 2013, Influence of CYP2D6 polymorphisms on serum levels of tamoxifen metabolites in Spanish women with breast cancer, Int J Med Sci, 10, 932, 10.7150/ijms.5708 · doi:10.7150/ijms.5708
  6. Hou, 1991, Salivary analysis for determination of dextromethorphan metabolic phenotype, Clin Pharmacol Ther, 49, 410, 10.1038/clpt.1991.48 · doi:10.1038/clpt.1991.48
  7. Dahl, 1992, Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population, Clin Pharmacol Ther, 51, 12, 10.1038/clpt.1992.2 · DOI · Paper page
  8. Sachse, 1997, Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences, Am J Hum Genet, 60, 284
  9. Ingelman-Sundberg, 2005, Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity, Pharmacogenomics J, 5, 6, 10.1038/sj.tpj.6500285 · DOI · Paper page
  10. Zhou, 2009, Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I, Clin Pharmacokinet, 48, 689, 10.2165/11318030-000000000-00000 · DOI · Paper page
  11. Cai, 2016, Effects of 22 Novel CYP2D6 Variants Found in the Chinese Population on the Bufuralol and Dextromethorphan Metabolisms in vitro, Basic Clin Pharmacol Toxicol, 118, 190, 10.1111/bcpt.12478 · DOI
  12. Qian, 2013, Genetic variations of human CYP2D6 in the Chinese Han population, Pharmacogenomics, 14, 1731, 10.2217/pgs.13.160 · DOI
  13. de Vries Schultink, 2015, Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen, Clin Pharmacokinet, 54, 797, 10.1007/s40262-015-0273-3 · DOI
  14. Brauch, 2014, Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer, Br J Clin Pharmacol, 77, 695, 10.1111/bcp.12229 · DOI
  15. Cronin-Fenton, 2014, Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy, Future Oncol, 10, 107, 10.2217/fon.13.168 · DOI
  16. Murdter, 2011, Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma, Clin Pharmacol Ther, 89, 708, 10.1038/clpt.2011.27 · DOI · Paper page
  17. Teunissen, 2011, Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques, J Pharm Biomed Anal, 55, 518, 10.1016/j.jpba.2011.02.009 · doi:10.1016/j.jpba.2011.02.009
  18. Binkhorst, 2015, Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping, Cancer Treat Rev, 41, 289, 10.1016/j.ctrv.2015.01.002 · DOI
  19. Wang, 2009, Novel DNA sequence variations of cytochrome P450 genes in the Han Chinese population, Pharmacogenomics, 10, 359, 10.2217/14622416.10.3.359 · doi:10.2217/14622416.10.3.359
  20. Griese, 2001, Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia, Pharmacogenetics, 11, 69, 10.1097/00008571-200102000-00008 · DOI
  21. Byeon, 2015, Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites, Arch Pharm Res, 38, 2083, 10.1007/s12272-015-0646-z · DOI
  22. Zhan, 2016, Effect of CYP2D6 variants on venlafaxine metabolism in vitro, Xenobiotica, 46, 424, 10.3109/00498254.2015.1089364 · doi:10.3109/00498254.2015.1089364
  23. Shen, 2007, Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17, Drug Metab Dispos, 35, 1292, 10.1124/dmd.107.015354 · DOI · Paper page
  24. Yu, 2002, Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms, J Pharmacol Exp Ther, 303, 1291, 10.1124/jpet.102.039891 · DOI
  25. Dai, 2015, In vitro functional assessment of 22 newly identified CYP2D6 allelic variants in the Chinese population, Basic Clin Pharmacol Toxicol, 117, 39, 10.1111/bcpt.12363 · doi:10.1111/bcpt.12363

Cited by

Metadata

Authors
Hu, X.-X., Zhou, Q., Lan, T., Huang, X.-X., Liang, B.-Q., Dai, D.-P., Cai, J.-P., & Hu, G.-X.
Affiliations
  • Department of Pharmacology, School of Pharmacy of Wenzhou Medical University , Wenzhou, Zhejiang,
  • The Key Laboratory of Geriatrics, Beijing Hospital & Beijing Institute of Geriatrics Ministry of Health , Beijing,
Venue
Journal of Pharmacy and Pharmacology
Published
2016-06-01
Volume
68
Issue
6
Pages
819-825
ISSN
  • 2042-7158
  • 0022-3573
Cited by
6
References
0
Language
en
Funders
  • National Health and Family Planning Commission of the People's Republic of China (201302008)
  • National Natural Science Foundation of China (31371280)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.